Welcome to our dedicated page for Profound Med SEC filings (Ticker: PROF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Profound Medical Corp. (PROF) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under Commission File Number 001-39032. Profound is a commercial-stage medical device company incorporated in Ontario, Canada that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Through its SEC filings, Profound reports material events related to its business and finances. Recent Form 8-K filings have covered topics such as preliminary unaudited financial results, business updates, and exclusive distribution and supply agreements for its TULSA-PRO® and Sonalleve® technologies in markets including Canada, Saudi Arabia, Australia and New Zealand. Other 8-Ks have furnished press releases announcing milestones like growth in the installed base of TULSA-PRO systems and developments in the company’s sales pipeline.
Investors can use these filings to track how Profound describes its revenue mix between recurring non-capital sources, such as TULSA-PRO consumables and equipment leases, and capital equipment sales, as well as to follow its equity financings, including registered direct offerings and private placements of common shares. Over time, annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks provide a structured record of the company’s financial condition, risk factors, and key operational metrics.
On Stock Titan, each new PROF filing is captured from EDGAR and paired with AI-powered summaries that highlight the main points, helping readers quickly understand the significance of lengthy documents. Users can review core filings such as 10-Ks and 10-Qs, along with current reports and any insider-related disclosures, to build a detailed view of Profound Medical’s regulatory and financial history.
Profound Medical Corp. filed a current report to note that it issued a press release on October 7, 2025 announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and providing a business update. The press release is furnished as Exhibit 99.1 under Item 2.02, which covers results of operations and financial condition. The company states that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Profound Medical Corp. furnished an update on its recent performance by reporting that it issued a press release with unaudited financial results for the three- and six-month periods ended June 30, 2025. The company also used the release to provide a broader business update.
The press release is attached as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced. This 8-K is a disclosure vehicle pointing investors to that detailed financial and operational information.